BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, Song G, Yuan Q, Yao Q, Shen X, Taubert R, Engel B, Jaeckel E, Vogel A, Falk CS, Schambach A, Gerovska D, Araúzo-Bravo MJ, Vondran FWR, Cantz T, Horscroft N, Balakrishnan A, Chevessier F, Ott M, Sharma AD. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 2021:S0168-8278(21)02006-7. [PMID: 34453962 DOI: 10.1016/j.jhep.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Sulaiman SA, Dorairaj V, Abdul Ghafar KN, Abdul Murad NA. Noncoding RNAs Interactions in Hepatic Stellate Cells during Hepatic Fibrosis. Livers 2021;1:263-85. [DOI: 10.3390/livers1040021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Karlinsey K, Qu L, Matz AJ, Zhou B. A novel strategy to dissect multifaceted macrophage function in human diseases. J Leukoc Biol 2022. [PMID: 35726704 DOI: 10.1002/JLB.6MR0522-685R] [Reference Citation Analysis]
3 Martínez-garcía J, Molina A, González-aseguinolaza G, Weber ND, Smerdou C. Gene Therapy for Acquired and Genetic Cholestasis. Biomedicines 2022;10:1238. [DOI: 10.3390/biomedicines10061238] [Reference Citation Analysis]
4 Dam TV, Toft NI, Grøntved L. Cell-Type Resolved Insights into the Cis-Regulatory Genome of NAFLD. Cells 2022;11:870. [DOI: 10.3390/cells11050870] [Reference Citation Analysis]
5 Chabanovska O, Galow AM, David R, Lemcke H. mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies. Adv Drug Deliv Rev 2021;179:114002. [PMID: 34653534 DOI: 10.1016/j.addr.2021.114002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Luo N, Zhong W, Li J, Lu J, Dong R. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges. Mol Biol Rep 2022. [PMID: 35960410 DOI: 10.1007/s11033-022-07713-6] [Reference Citation Analysis]
7 Zabaleta N, Torella L, Weber ND, Gonzalez-Aseguinolaza G. mRNA and gene editing: Late breaking therapies in liver diseases. Hepatology 2022. [PMID: 35243655 DOI: 10.1002/hep.32441] [Reference Citation Analysis]
8 Szabo G, Thursz M, Shah VH. Therapeutic advances in alcohol-associated hepatitis. J Hepatol 2022;76:1279-90. [PMID: 35589250 DOI: 10.1016/j.jhep.2022.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]